Showing 101 - 120 results of 100,531 for search '(( 16 w decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.46s Refine Results
  1. 101

    Response of small airway tissues infected with EV-D94 and decreasing doses of EV-D68. by Ines Cordeiro Filipe (5849144)

    Published 2022
    “…<p>Tissues were infected with 1E7 RNA copies of EV-D94 (equivalent to 2,46E4 TCID50) and 1E7 RNA copies of EV-D68 (3,3E5 TCID50) as well as decreasing doses of the latter. …”
  2. 102
  3. 103
  4. 104

    Increases in 1,5-anhydrosorbitol and decreases in ascorbic acid following RYGB. by David M. Mutch (37665)

    Published 2013
    “…B) For ascorbic acid, the ANOVA model did not detect group-specific changes over time (no group:time interaction), but indicated significant decreases from T0 to T6 in both groups. Overall, 1,5-anhydrosorbitol and ascorbic acid were significantly different at each time point between OB and OB/D subgroups (p<0.01, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0007905#pone-0007905-t002" target="_blank"><b>TABLE 2</b></a>).…”
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112

    Ether induces proteotoxic stress, leading to a decrease in Trx protein and an increase in Hsp90 clients that are joint targets of Trx and Ubx. by Orli Snir (18625811)

    Published 2024
    “…<i>p</i> > 0.05, Student’s <i>t</i> test. <b>(M)</b> Median fold-change (ether/ctrl) of protein levels in the following subsets of Hsp90 clients (left to right): All clients (<i>n</i> = 280), Hsp90 w/o Trx or Ubx targets (<i>n</i> = 197), Hsp90 and Trx but not Ubx targets (<i>n</i> = 52), Hsp90 and Trx targets (<i>n</i> = 69), Hsp90 and Ubx targets (<i>n</i> = 31), Hsp90 and Trx and Ubx targets (<i>n</i> = 16). …”
  13. 113
  14. 114

    Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

    Published 2022
    “…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC<sub>(tofacitinib, 0–∞)</sub> and a 9.61-fold increase of colonic AUC<sub>(tofacitinib, 0–12h)</sub>, compared with tofacitinib at a molar equivalent oral dose. …”
  15. 115
  16. 116
  17. 117
  18. 118
  19. 119
  20. 120